# Beisi Biology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beisi-biology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.basetherapeutics.com
- Total disclosed funding: $15M
- Latest round: Series A (Sep 12, 2024)
- Investors on record: 10

## About

Established in 2021 and based in Shanghai, China, Beisi Biology operates as a biotechnology company dedicated to providing NK cell tumour treatment and gene editing technologies. It has a sub-branch office in America. The founding team most from Stanford University School of Medicine, Baylor College of Medicine and MD Anderson Cancer Center. The company has obtained 29 intellectual property applications, covering software copyright, utility model patents, national invention patents, PCT and US patents. In September 2024, it closed series A2 funding led by new investor Gobi Partners.

The company provides NK cell tumour treatment and gene editing technologies and related products. It has developed nearly 200 base editing tools. Its pipeline includes NK cells, super-NK, super-ipsc NK(iNK) and in vivo. And products can apply in biologics, agriculture and new tools fields, and be achieved zero off-target. The product is suitable for a variety of solid tumours including lung cancer, liver cancer, brain glioma, etc.

The company generates revenue by providing NK cell tumour treatment, gene editing technologies, and related products.

The company will use the funding to strengthen the R&D team, optimize the product pipeline, and accelerate clinical trials.

## Funding rounds

- Series A, Sep 12, 2024 — Gobi Partners
- Series A, Jan 16, 2023 — SPARK Ventures, Great Eagle Holdings, HighLight Capital, Baidu Ventures, Sincere Capital, Beijing Guangda Huitong Engineering Research Institute
- Angel, Jul 26, 2021, $15M — HighLight Capital, Virtus Inspire Ventures, Panacea Venture, Hengqin Financial Investment

## Investors

- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Angel, Series A
- Virtus Inspire Ventures (https://capitalatlas.ai/funds/virtus-inspire-ventures) — Angel
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Angel
- Hengqin Financial Investment (https://capitalatlas.ai/funds/hengqin-financial-investment) — Angel
- SPARK Ventures — Series A
- Great Eagle Holdings — Series A
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series A
- Sincere Capital (https://capitalatlas.ai/funds/sincere-capital) — Series A
- Beijing Guangda Huitong Engineering Research Institute — Series A
- Gobi Partners (https://capitalatlas.ai/funds/gobi-partners) — Series A